Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.63 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | PAM | P19021 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106773 | 1.00 | HTR2A (0.63) | HTR2ACTSCTP53MAPTGRIK1 | |
| SCHEMBL14037582 | 0.90 | HTR2A (0.70) | HTR2AGRIK1GRIK2IDO1PAM | |
| SCHEMBL6289214 | 0.85 | HTR2A (0.59) | HTR2ACTSCTP53GRIK1GRIK2 | |
| SCHEMBL25189137 | 0.82 | HTR2A (0.61) | HTR2AGRIK1GRIK2IDO1PAM | |
| SCHEMBL6286622 | 0.82 | HTR2A (0.60) | HTR2ACTSCGRIK1GRIK2IDO1 | |
| SCHEMBL2170349 | 0.81 | HTR2A (0.70) | HTR2AGRIK1GRIK2IDO1PAM | |
| SCHEMBL107852 | 0.81 | HTR2A (0.70) | HTR2AGRIK1GRIK2IDO1PAM | |
| SCHEMBL107851 | 0.81 | HTR2A (0.70) | HTR2AGRIK1GRIK2IDO1PAM | |
| SCHEMBL105715 | 0.81 | APP (0.42) | HTR2AMAPT | |
| SCHEMBL21569429 | 0.81 | HTR2A (0.59) | HTR2AGRIK1GRIK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-11821047-B2 | High pressure zone formation for pretreatment | Apalta Patent OÜ (EE) | 2023-11-21 | — | — | US | disclosed |
| EP-4098750-A1 | RAPID PRETREATMENT | Sweetwater Energy, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3230463-B1 | RAPID PRETREATMENT | SWEETWATER ENERGY INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11332723-B2 | Engineered microorganisms for production of commodity chemicals and cellular biomass | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220090156-A1 | Methods and Systems For Saccharification of Biomass | APALTA TEHNOLOOGIA OÜ (EE) | 2022-03-24 | — | — | US | disclosed |
| WO-2010104896-A1 | PRODUCTION OF FERMENTIVE END PRODUCTS FROM CLOSTRIDIUM SP. | QTEROS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20100086981-A1 | COMPOSITIONS AND METHODS FOR IMPROVED SACCHARIFICATION OF BIOMASS | QTEROS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20090203089-A1 | ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF | BIO ARCHITECTURE LAB, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | HTR2A 3731/4885CTSC 1975/4885TP53 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.